Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant

SARS-COV-2 Clinical Trial

— LA-COVID  

Official title:

Description of a Cohort of Covid-19 Patients With a Circulating Anticoagulant

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05075928
• Other study ID #: 7861
• Status: Recruiting
• Start date: June 1, 2020
• Est. completion date: November 2021

Study information

• Verified date: October 2021
• Source: University Hospital, Strasbourg, France
• Contact: Anne-Sophie Korganow, MD, PhD
• Phone: 33 3 69 55 05 21
• Email: Anne-sophie.Korganow[@]chru-strasbourg.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

SARS-COV-2 infection is responsible for a potentially severe primarily respiratory infection called COVID19. A large proportion of patients, in particular in severe forms, present with thrombotic manifestations (DVT, EP, stroke, thrombosis of dialysis circuits, etc.). A significant proportion is also a carrier of circulating anticoagulant (ACC or LA), making it possible to suggest a diagnosis of APS. This type of autoantibody results in a spontaneous prolongation of the TCA uncorrected by a control serum therefore is quickly diagnosed using standard hemostasis The objective of this study is to describe the diagnosis of thrombotic complications in COVID19 patients presenting a positive lupus anticoagulant type test (LA) or aPL and the associated clinical and biological elements that may have favored thrombosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: November 2021
• Est. primary completion date: November 2021
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion criteria:

• Adult patient (=18 years old)

• Patient taken care of in the SMO pole or the NHC surgical resuscitation service or hospitalized or consultant to the HUS between 01/03/2020 and 31/05/2020

• Patient infected with Covid-19, with a documented infection, having presented a documented thrombosis (arterial or venous), with an LA or aPL in the thrombosis assessment

• or Patient infected with Covid-19, with a documented infection, without documented thrombosis (arterial or venous), with in the standard work-up an increase in TCA revealing the presence of LA

• Subject having given his agreement for the reuse of his data for the purposes of this research

Exclusion criteria:

• Subject having expressed opposition to participating in the study

• Subject under guardianship or guardianship

• Subject under safeguard of justice

Related Conditions & MeSH terms

• COVID-19
• SARS-COV-2

Locations

Country	Name	City	State
France	Service de Médecine Interne et d'Immunologie Clinique - Hôpitaux Universitaires de Strasbourg	Strasbourg

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Strasbourg, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Retrospective study of thrombotic complications in a cohort of COVID patients with a circulating anticoagulant		Files analysed retrospectively from March 01, 2020 to May 31, 2019 will be examined]